

BASH UK Clinical Practice Recommendations for Advanced Migraine Treatments

Dr Gina Kennedy, Prof Alexandra Sinclair, Dr Jane Anderson, Dr Anish Bahra, Sr Claire Fisher

Dr Mona Ghadiri-Sani, Dr Salwa Kamourieh, Dr Michael Long, Dr Benjamin Wakerley,

Dr David Watson, Dr Mark Weatherall, Dr Brendan Davies


<https://bash.org.uk>

info@bash.org.uk



In line with BASH values to educate professionals, empower patients and promote excellence in headache care, BASH has developed a list of clinically relevant practical recommendations to help standardise migraine management.

Onabotulinum Toxin A / CGRP monoclonal antibodies / Gepants



Join BASH today: <https://bash.org.uk>

Background:

- The recent development of a wide range of CGRP-targeted migraine treatments, in addition to botulinum toxin, has widened the choice of advanced migraine treatment options for clinicians and migraine sufferers more than ever before. Although this is an exciting era, there is a lack of consistency of use and treatment accessibility across the UK

Methods:

- The BASH consensus group was composed of a representative sample of headache specialist expertise from different perspectives including specialist nurses, consultants and GPs with extended roles across the UK.
- A list of frequently asked questions was reviewed and agreed by consensus agreement.
- Practical recommendations were compiled via an evidence-based, group consensus approach. Each recommendation was based on a selected search of evidence-based guidelines, meta-analyses, and systematic reviews. Principles were based on national standards of care and consensus agreement.
- The final recommendations were discussed with the full BASH Council Group for voting and final approval. The minimum agreed percentage criteria was 75%.

Conclusion:

A set of practical recommendations on advanced migraine treatment options are presented covering areas such as the definition of treatment efficacy, management of medication overuse, when to start, combine or stop preventative treatment, and what co-morbidities to consider. The aim is to improve and standardise migraine treatment UK-wide.